Invasive candidiasis (IC) continues to be a leading cause of healthcare-associated bloodstream infections, carrying substantial mortality rates. While historically dominated by Candida albicans, a global epidemiological shift toward non-albicans Candida (NAC) species is currently complicating treatment due to their variable and often reduced susceptibility to azoles, the most common antifungal class.-This study hypothesizes that significant antibiotic pressure is a key driver behind the emergence of resistant NAC species in Iranian healthcare settings. To investigate this, a systematic literature search was conducted across international databases, including PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, alongside Iranian national databases such as SID, Magiran, and IranMedex, for relevant studies published between January 2015 and December 2024. Our analysis of 30 eligible studies confirms a critical epidemiological shift in Iran, where NAC species collectively account for 55–65% of clinical isolates in recent reports, thereby superseding C. albicans as the most prevalent pathogens. Among these, C. glabrata and C. tropicalis have emerged as the predominant NAC species, exhibiting alarmingly high fluconazole resistance rates of 30–40% and 20–25%, respectively. Furthermore, the emergence of the multidrug-resistant C. auris has been documented, with these trends being most pronounced in clinical settings with high antibiotic use, such as Intensive Care Units (ICUs), underscoring a strong link between antibiotic pressure and the selection of resistant fungal pathogens. These findings suggest that the landscape of invasive candidiasis is undergoing a dangerous transformation. This crisis demands an urgent, multifaceted national response, including the immediate implementation of robust antimicrobial stewardship programs, the establishment of a national fungal surveillance network, and the revision of empiric antifungal therapy guidelines in favor of echinocandins in high-risk settings. Additionally, significant investment in advanced diagnostic capacity for rapid species identification and antifungal susceptibility testing is essential to mitigate this escalating public health threat.